Poseida Therapeutics, Inc.

This early-phase study tests an investigational cell therapy called P-MUC1C-ALLO1 in adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The main goals are to find a safe dose and check for early sign…

This study follows about 100 people with multiple myeloma who have already received the experimental cell therapy P-BCMA-101. Researchers will track them for up to 15 years to check for delayed side effects and see how long the treatment's anti-cancer effects last. The goal is to…

This early-phase study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell lymphoma that have come back or not responded to standard therapy. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The m…

This early-stage study tests an experimental therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses donor immune cells engineered to target and kill myeloma cells. The main goals are to check …